Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain conservative and supported by current metrics.
SENTINEL REVIEW
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)•Updated yesterday
🚨 Structural Deterioration Signature: In FY2026, Aarey Drugs & Pharmaceuticals Limited is experiencing operating deterioration, marked by a 1.4% YoY decline in reported net profit to ₹4.0 Cr and persistent negative operating leverage. Profitability is being strained by margin compression: EBITDA margins fell to 0.18% from 1.18% YoY, signaling significant cost-push pressure and structural stress. This operating strain is reflected in severe inventory stress and working capital expansion: inventory levels rose 31.1% YoY while revenue contracted 19.2%, contributing to a 5.0% drop in operating cash flow to ₹10.1 Cr. Against this liquidity strain, total debt expanded 43.3% to ₹50.0 Cr, pushing interest coverage down to 1.31x and triggering heightened surveillance.
- ✓Risk score improved (QoQ change: -2 pts)
- ✓Profitability margins pressure eased
- ✗New risk trigger: Other Income Dependency (+8 pts)
- ✓Growth expectations are conservative
- ✓Market structure is strong
- ✗Institutional flow regime is Neutral (0.14σ)
- ✓Share price is up +5.2% this quarter (from ₹102.72 on 30 Sept to ₹108.05)
- 🔴Investigate Low Interest Coverage and balance sheet impact
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 11.5 ptsBalance Sheet Stress
- 6.0 ptsEarnings Quality
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -3.47% | -1.46% | -2% |
| 1 Month | +8.56% | -6.69% | +15.25% |
| 6 Months | +18.63% | +6.82% | +11.81% |
| 1 Year | +18.36% | +8.93% | +9.43% |
| 2 Year | +87.39% | +47.64% | +39.75% |
| 3 Year | +159.42% | +125.5% | +33.93% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure is receding in balance sheet stress. This indicates that forensic pressure is currently receding. Minor improvements are visible in the risk trend.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 10 → 18 over 12 quarters.
- Interest coverage ratio
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Other Income Dependency is currently the primary contributor to forensic pressure. Ongoing monitoring of cash generation and balance sheet quality is warranted in upcoming quarters.
Active Risk Objects (9)Free Preview (2 of 9)
AAREYDRUGS: 332.6% of PBT derived from Other Income in Q1 FY2027 (Other Income: ₹1.7 Cr vs PBT: ₹0.5 Cr).
Early signs of earnings quality decay. Profitability is being driven by non-core items.
AAREYDRUGS: Low Interest Coverage Ratio of 1.31x in FY2027 Q1 (Threshold: 2.5x).
Interest coverage is dangerously low. Even a minor fall in profit could trigger a default.
Unlock All 9 Forensic Signals (7 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 9 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Aarey Drugs & Pharmaceuticals Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Aarey Drugs & Pharmaceuticals Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-2.0 pts), driven by overall risk reduction across core indicators, partially offset by new Other Income Dependency (+8.0 pts) and Low Interest Coverage (+3.8 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated notably (+12.0 pts), driven by new Working Capital Expansion (+10.8 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Watch
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Aarey Drugs & Pharmaceuticals Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·5 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 130 | 130 | 0 | 190 | — |
Inventories(₹ Cr) | 42 | 45 | 35 | 29 | — |
Trade Payables(₹ Cr) | 82 | 54 | 129 | 127 | — |
Net Working Capital(₹ Cr) | 90 | 121 | -94 | 91 | — |
Working Capital / Sales(%) | 18.7% | 25.0% | -23.4% | 145.0% | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 69d | 91d | -86d | 529d | — |
Debtor Days (DSO)(days) | 99d | 98d | 0d | 1100d | — |
Inventory Days (DIO)(days) | 32d | 34d | 31d | 167d | — |
Creditor Days (DPO)(days) | 62d | 41d | 117d | 738d | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | +1.1% | — | -639.5% | — | — |
Inventory Growth vs Sales (Δ)(%) | -7.6% | +11.0% | -519.2% | — | — |
Asset Growth vs Sales (Δ)(%) | +25.9% | -42.0% | -534.8% | — | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | -6 | -6 | -3 | 40 | -11 |
Accrual Ratio (Accruals / Avg Assets)(%) | -2.3% | -2.1% | -1.1% | 13.6% | — |
Operating Cash Realisation (CFO / EBITDA)(%) | 187.3% | 158.2% | 147.7% | -5241.8% | 185.4% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q1 FY2027 | 6.2% | +100 bps ↑ Operating efficiency gains | -410 bps ↓ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹108, the market expects this company to grow its revenue by -4.2% every year for the next 5 years. If you think the company will grow faster than -4.2%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market currently expects future growth below the company's historical delivery record. Expectations appear conservative relative to the business's track record, resulting in lower expectation risk.
Using the Implied Revenue Model, the market is pricing AAREYDRUGS for -4.2% implied revenue growth versus 20.0% observed 3Y revenue CAGR. Current expectations appear conservative, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | -4.2% | 20.0% | Achievable |
| Operating Margin (EBIT) | 1.0% | 1.2% | Achievable |
| Free Cash Flow Conversion | -54.1% | 88.0% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance below the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Although institutional participation has weakened, trend quality remains constructive while momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Market structure shows partial alignment with the underlying fundamental risk profile.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on AAREYDRUGS & 3 market anomalies weekly
See a sample issue →